Hanson & Doremus Investment Management Vertex Pharmaceuticals Inc Transaction History
Hanson & Doremus Investment Management
- $748 Million
- Q2 2025
A detailed history of Hanson & Doremus Investment Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hanson & Doremus Investment Management holds 570 shares of VRTX stock, worth $219,820. This represents 0.03% of its overall portfolio holdings.
Number of Shares
570
Previous 370
54.05%
Holding current value
$219,820
Previous $179,000
41.9%
% of portfolio
0.03%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding VRTX
# of Institutions
1,828Shares Held
232MCall Options Held
1.49MPut Options Held
1.07M-
Capital World Investors Los Angeles, CA28.5MShares$11 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$9.06 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.22 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$5.61 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.55 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $99B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...